ArticleBiomaterials2014
Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles.
Article in Biomaterials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 49 citations in OpenAlex.
- Liposomes in tumor treatment: a double-edged sword.Science China. Life sciences · 2026Review
- Enhanced immunocompatibility and hemocompatibility of nanomedicines across multiple species using complement pathway inhibitors.Science advances · 2025Article
- Native C3 is activated without proteolytic cleavage by transformation to C3(HFrontiers in immunology · 2025Article
- Ginsenoside modified lipid-coated perfluorocarbon nanodroplets: A novel approach to reduce complement protein adsorption and prolongActa pharmaceutica Sinica. B · 2024Article
- Biological Features of Nanoparticles: Protein Corona Formation and Interaction with the Immune System.Pharmaceutics · 2022Review
- Role of Surface Charge of Nanoscale Ultrasound Contrast Agents in Complement Activation and Phagocytosis.International journal of nanomedicine · 2022Article
- Complement opsonization of nanoparticles: Differences between humans and preclinical species.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Subvisible Particles in IVIg Formulations Activate Complement in Human Serum.Journal of pharmaceutical sciences · 2020Article
- Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine.Frontiers in immunology · 2020Review
- Formation of Protein Corona on Nanoparticle Affects Different Complement Activation Pathways Mediated by C1q.Pharmaceutical research · 2019Article
- The Interplay Between Blood Proteins, Complement, and Macrophages on Nanomedicine Performance and Responses.The Journal of pharmacology and experimental therapeutics · 2019Review
- Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- A human whole-blood model to study the activation of innate immunity system triggered by nanoparticles as a demonstrator for toxicity.Science and technology of advanced materials · 2019Review
- Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population.Bioconjugate chemistry · 2017Article
- Complement activation turnover on surfaces of nanoparticles.Nano today · 2017Article
- Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention.Molecular oral microbiology · 2016Review
- Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18.Thrombosis and haemostasis · 2015Article
- Complement--tapping into new sites and effector systems.Nature reviews. Immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 4 countries.
Funding
Abstract
Liposomes are becoming increasingly important as drug delivery systems, to target a drug to specific cells and tissues and thereby protecting the recipient from toxic effects of the contained drug. Liposome preparations have been described to activate complement. In this study, we have investigated complement activation triggered by neutral dimyristoyl-phosphocholine (DMPC) liposomes in human plasma and whole-blood systems. Incubation in plasma led to the generation of complement activation products (C3a and sC5b-9). Unexpectedly, investigations of surface-bound C3 revealed contact activated, conformationally changed C3 molecules on the liposomes. These changes were characterized by Western blotting with C3 monoclonal antibodies, and by incubating liposomes with purified native C3 and factors I and H. Quartz crystal microbalance analysis confirmed binding of C3 to planar DMPC surfaces. In addition, we demonstrated that DMPC liposomes bound to or were phagocytized by granulocytes in a complement-dependent manner, as evidenced by the use of complement inhibitors. In summary, we have shown that C3 is activated both by convertase-dependent cleavage, preferentially in the fluid phase, by mechanisms which are not well elucidated, and also by contact activation into C3(H2O) on the DMPC surface. In particular, this contact activation has implications for the therapeutic regulation of complement activation during liposome treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.